Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Alzheimer disease (AD) is the leading cause of dementia, with an estimated 6.9 million Americans aged 65 and older living with Alzheimer dementia today, with this number projected to grow to 13.8 million by 2060.
Why it matters
This article describes how amyloid and tau PET imaging is used for diagnosis, triage, and monitoring of patients with neurodegenerative disease, especially after approval of anti-amyloid monoclonal antibody therapies for early-stage Alzheimer disease. It focuses on the evolving role of imaging in clinical practice, including challenges of reimbursement and workforce capacity.
-
ADOD cases have steadily increased, with projections indicating continued growth by 2030.
Why it matters
This study projects that Alzheimer's disease and other dementias will continue rising in Japan through 2030, with high fasting plasma glucose, obesity, and smoking as significant modifiable risk factors. It supports targeted policies and prevention efforts but does not test a treatment or cure.
-
The vast majority of CAA remains sporadic, with increasing prevalence with age and very frequent coexistence with Alzheimer’s disease.
Why it matters
This review states that no targeted therapy for cerebral amyloid angiopathy currently exists, and that management remains challenging, especially when markers of higher bleeding risk are present. It notes that various clinical trials are in progress, but reports no treatment that cures or prevents the disease.
-
In 2021, Asia experienced a 250.44% increase in prevalent cases, a 297.34% rise in mortality, and a 249.54% surge in DALYs for AD and other dementias compared to 1990.
Why it matters
This analysis describes large increases in dementia cases, deaths, and disability across Asia since 1990, with the burden highest in women, people 65 and older, and East Asia. It identifies smoking, high fasting plasma glucose, and high BMI as risk factors but tests no treatment, cure, or prevention.
-
Forty-four physicians, primarily neurologists (n = 31; 70.5 %), were interviewed.
Why it matters
This study surveyed physicians in Asia and found that most patients with mild cognitive impairment due to Alzheimer's disease were treated with nootropics and/or acetylcholinesterase inhibitors, and almost all received non-pharmacological recommendations. Barriers to diagnosis included low disease awareness and limited access to biomarker tests, but no new treatment is tested.
-
The protein composition of tear fluid (TF) reflects the severity and progression of many age-related diseases.
Why it matters
In a small study of 53 people, 14 proteins related to neuroinflammation showed altered levels in tear fluid from those with mild Alzheimer's disease compared with healthy controls. This is biomarker research only and does not show that measuring these proteins can treat, cure or prevent the disease.
-
42/100
Multitarget drugs are molecules with the ability to act simultaneously on different targets at the same time, and they have been evaluated in the last decade as a powerful tool in the development of promising therapeutics for neurodegenerative diseases.
Why it matters
This review discusses multitarget drugs that act on more than one biological target as a strategy for Alzheimer's, Parkinson's, and Huntington's diseases. It argues that single-target drugs are inadequate for these complex diseases but does not report a proven therapy.
-
Alzheimer's disease (AD) is a devastating form of dementia, with the number of affected individuals rising sharply.
Why it matters
This review describes the hallmarks of Alzheimer's disease and frontotemporal dementia and notes that currently approved medications are only symptomatic, with no disease-modifying therapy available to halt progression. The authors suggest that multi-targeted therapeutic approaches could hold promise for treating these conditions.
-
A growing body of literature has examined the impact of neighborhood characteristics on Alzheimer’s disease (AD) dementia, yet the spatial variability and relative importance of the most influential factors remain underexplored.
Why it matters
This study found that factors such as mobile homes, green space, physical inactivity, households with no vehicle and particulate matter were the most influential factors for Alzheimer's disease dementia prevalence in different U.S. counties. It suggests county-specific policies such as improving housing stability, green spaces, transportation, physical activity and air pollution, but it does not test any treatment or cure.
-
Neuro Degenerative Disorders (NDDs) involve progressive nerve cell loss, impacting functions like sensation, movement, memory, and cognition, posing life-threatening risks.
Why it matters
This paper groups explainable artificial intelligence methods used in studies of neurodegenerative disorders, including Alzheimer's disease, and notes gaps such as the lack of security frameworks and difficulty using these methods in real healthcare settings. It tests no treatment, cure, or prevention.
-
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlighted the virus's impact on the central nervous system and its potential to exacerbate neurodegenerative diseases, similar to that in Alzheimer disease (AD).
Why it matters
This review explores shared mechanisms such as blood-brain barrier dysfunction and neuroinflammation that may link SARS-CoV-2 infection to Alzheimer's disease onset or progression. It proposes convergent pathways but does not show that COVID-19 causes Alzheimer's or that any treatment prevents it.
-
Of 44,899 MCI patients, 6391 progressed to AD.
Why it matters
Using electronic health records from multiple institutions, federated learning improved prediction of progression from mild cognitive impairment to Alzheimer's disease by 6% in AUC compared to local models. This is a prediction tool, not a treatment, cure or prevention.
-
The subdivisions exhibit different pathways, terminations, and structural characteristics.
Why it matters
This study found microstructural differences in subdivisions of the cingulum bundle between Alzheimer disease, mild cognitive impairment, and cognitively normal subjects. The authors state that a larger sample is needed to confirm results and clarify the role of diffusion parameters in progression to dementia.
-
Significant amygdala atrophy was observed in multiple amygdala nuclei across cognitive performance groups, with more pronounced changes in the low-performance group.
Why it matters
This cross-sectional study found amygdala atrophy across cognitive performance groups, with more pronounced changes in the low-performance group and more significant differences in right hemisphere nuclei. The authors state that larger sample sizes and longitudinal designs are needed to confirm these findings and determine their diagnostic value.
-
6.98 [2.44-19.95]; p < 0.05) driven primarily by self-identified Black race and age, while none with A and T. ASCVD risk score was also associated with WMHs ((β=0.42 ± 0.22; p = 0.05).
Why it matters
In an asymptomatic, diverse cohort, midlife cardiovascular risk score predicted later neurodegeneration and white matter hyperintensities but not amyloid or tau. The authors call for further studies to see whether midlife cardiovascular risk factors initiate brain vulnerability leading to Alzheimer's disease.
-
Plasma ptau217 has strong diagnostic performance in distinguishing CSF biomarker-defined AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patient's symptoms.
Why it matters
Among 79 younger patients, plasma ptau217 distinguished biomarker-defined Alzheimer's disease from other conditions with 90% accuracy. This is a diagnostic accuracy study in a small cohort and does not test any treatment, cure, or prevention.
-
42/100
This Alzheimer's Association workgroup paper proposes a major update to how Alzheimer's disease is diagnosed: it defines the disease by biological markers (amyloid plaques and tau tangles detected via blood, CSF, or PET) rather than requiring clinical symptoms like memory loss to be present.
Why it matters
Presymptomatic Alzheimer's disease can now be identified through blood biomarkers under revised diagnostic criteria, potentially enabling treatment to begin before cognitive symptoms appear. Blood-based biomarkers are incorporated into the diagnostic framework for the first time, providing an additional method for disease identification beyond cerebrospinal fluid and PET imaging.
-
The authors sought to examine the impact of the K-variant of butyrylcholinesterase (BCHE-K) carrier status on age-at-diagnosis of Alzheimer disease (AD) in APOE4 carriers.
Why it matters
In a post-hoc analysis of 45 patients with biomarker-confirmed Alzheimer's disease, those carrying both APOE4 and the butyrylcholinesterase K variant were diagnosed about 6.4 years earlier on average. It is about genetic influences on age at diagnosis, not about treating, curing or preventing the disease.
-
The purpose is to review the latest advances of brain imaging for the diagnosis of Alzheimer disease (AD).
Why it matters
This review describes how amyloid PET helps determine the window for anti-amyloid therapies and how tau PET is important for tracking progression and monitoring trials. It notes that PET for microglial activation, astrocyte reactivity and synaptic degeneration is still research-only, and it does not report a treatment, cure or prevention.
-
Recent high-profile failures of Alzheimer disease treatments at the clinical trial stage have led to renewed efforts to identify and test novel interventions for Alzheimer disease and related dementias (ADRD).
Why it matters
This perspective argues that well-designed observational studies are an important complement to preclinical studies and randomized controlled trials in Alzheimer's disease research. It does not report new treatment results, but discusses how observational research can help generate hypotheses and bridge the gap to successful interventions.
-
Alzheimer disease (AD) is the most common neurodegenerative disease and typically affects patients older than age 65.
Why it matters
This review discusses advanced drug trials focused on reducing brain beta-amyloid to prevent and treat dementia, and notes that at present Alzheimer's disease can be definitively diagnosed only through postmortem brain biopsies. It describes the state of drug development rather than reporting a proven cure or prevention.
-
We retrospectively assessed participants with atypical and/or early-onset dementia evaluated at a tertiary care memory clinic.
Why it matters
This study looked at how often spinal fluid biomarkers and FDG-PET scans agree or disagree when evaluating atypical and early-onset dementia cases. It is a diagnostic comparison and does not test any treatment or cure.
-
Human genetic and animal model studies indicate that brain microglial inflammation is a primary driver of cognitive impairment in Alzheimer Disease (AD).
Why it matters
In aged Alzheimer disease mice, the Casp1 inhibitor VX-765 improved episodic and spatial memory even eight months after cognitive impairment began, and this improvement tracked with recovery of dendritic spine density and hippocampal synaptophysin. However, VX-765 only slightly decreased Aβ deposition, did not change biochemically measured Aβ levels, and did not alter microglial or astrocyte markers or IL-1β and TNF-α, so these animal findings point to neuronal degeneration rather than Aβ or inflammation as the driver of cognitive impairment.
-
In this study, we investigated the possible role of 2 novel biomarkers of synaptic damage, namely, neurogranin and α-synuclein, in Alzheimer disease (AD).
Why it matters
In this cohort, cerebrospinal fluid levels of neurogranin and α-synuclein were higher in patients with Alzheimer disease than in those without it, and neurogranin correlated with tau markers. This is a biomarker study and does not test any treatment or show that these markers can be used to prevent or cure the disease.
-
Alzheimer's disease neuropathological comorbidities are highly prevalent even in the younger-old.
Why it matters
This survey found that Alzheimer's disease dementia is often accompanied by other neurodegenerative and cerebrovascular diseases that are not detected clinically. These comorbidities were common even in younger-old people, and pure Alzheimer's disease was in the minority even in the under-60 group.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Dysfunction of the episodic memory network in the Alzheimer’s disease cascade
- The role of TNF and its receptors in Alzheimer's disease
- A review on recent advances in Alzheimer's disease: The role of synaptic plasticity
- β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies
- Spicy food consumption is associated with cognition and cerebrospinal fluid biomarkers of Alzheimer disease
- New and emerging drug therapies for Alzheimer disease
- Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research
- Alzheimer’s related dementia severity classification from magnetic resonance imaging using derivative-free optimization of convolutional neural network
- Brexpiprazole for treating agitation in different groups of people with Alzheimer’s dementia: a plain language summary
- PET Imaging in Alzheimer Disease: Diagnostic and Prognostic Applications